ArticleJournal of nanobiotechnology2026
Microenvironment-responsive nanomotors enable enhanced biofilm penetration and immune reprogramming for peri-implantitis therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A pH-Switchable Cerium Single-Atom Enzyme for Peri-Implantitis Therapy via JAK-STAT Signaling Axis-Mediated Macrophage Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Research advances in early diagnosis and treatment strategies for peri-implantitis: from microecology to regenerative therapy.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPeri-implantitis is driven by persistent multispecies biofilms and a pathological inflammatory microenvironment characterized by elevated reactive oxygen species (ROS), acidic pH, and sustained pro-inflammatory macrophage activation. These coupled features severely limit the efficacy of conventional antimicrobial therapies by restricting drug penetration into mature biofilms and perpetuating immune dysregulation. Therapeutic strategies capable of simultaneously overcoming biofilm mass-transport barriers and restoring immune homeostasis remain lacking.
resultsHerein, we report a microenvironment-responsive nanomotor system (M-CaO₂-CL) that converts pathological inflammatory cues into sustained autonomous motion, enabling active biofilm penetration and concurrent immunomodulation. Triggered by elevated hydrogen peroxide (H₂O₂) and sustained by acidic pH, the nanomotors generate continuous oxygen-driven propulsion, facilitating deep infiltration into dense biofilm matrices and overcoming diffusion-limited transport. This motion-enabled behavior markedly enhances antibacterial efficacy, particularly when combined with mild photothermal treatment under near-infrared irradiation (< 48 °C), achieving efficient biofilm disruption without detectable collateral tissue damage. Beyond antibiofilm activity, the nanomotor platform exhibits intrinsic antioxidant and anti-inflammatory functions, effectively scavenging excessive ROS and reprogramming macrophages from a pro-inflammatory M1 phenotype toward a reparative M2 phenotype. In a rat peri-implantitis model, M-CaO₂-CL treatment significantly reduced bacterial burden, suppressed pro-inflammatory cytokine expression, and preserved peri-implant bone architecture.
conclusionsCollectively, this study demonstrates a multifunctional nanomotor-based therapeutic strategy that integrates inflammation-responsive propulsion, enhanced biofilm penetration, mild photothermal disinfection, and immune reprogramming. By harnessing pathological microenvironmental cues as endogenous driving forces, the M-CaO₂-CL nanomotor effectively addresses key biological barriers in peri-implantitis, establishing a promising nanotherapeutic platform for biofilm-associated inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.